ExpreS2ion Biotech Holding AB (publ) (EXPRS2.ST)
SEK 19.08
(-1.45%)
SEK 19.08
(-1.45%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.71 Million SEK | -7.56% |
| 2022 | 1.85 Million SEK | -3.49% |
| 2021 | 1.91 Million SEK | -19.41% |
| 2020 | 2.38 Million SEK | 59.41% |
| 2019 | 1.49 Million SEK | 61.58% |
| 2018 | 924 Thousand SEK | 1132.0% |
| 2017 | 75 Thousand SEK | -98.72% |
| 2016 | 5.87 Million SEK | 410.74% |
| 2015 | 1.14 Million SEK | 112.46% |
| 2014 | 541.14 Thousand SEK | 716.47% |
| 2013 | 66.27 Thousand SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 2.04 Million SEK | 602.41% |
| 2024 Q1 | 291 Thousand SEK | -82.99% |
| 2023 Q3 | 2.08 Million SEK | -1.47% |
| 2023 Q4 | 1.71 Million SEK | -17.94% |
| 2023 Q1 | 2 Million SEK | 8.37% |
| 2023 Q2 | 2.11 Million SEK | 5.48% |
| 2023 FY | 1.71 Million SEK | -7.56% |
| 2022 Q1 | 1.86 Million SEK | -2.87% |
| 2022 FY | 1.85 Million SEK | -3.49% |
| 2022 Q4 | 1.85 Million SEK | 2.27% |
| 2022 Q3 | 1.81 Million SEK | -1.04% |
| 2022 Q2 | 1.82 Million SEK | -1.83% |
| 2021 Q1 | 1.92 Million SEK | -19.03% |
| 2021 Q3 | 1.96 Million SEK | -0.31% |
| 2021 Q2 | 1.96 Million SEK | 2.02% |
| 2021 FY | 1.91 Million SEK | -19.41% |
| 2021 Q4 | 1.91 Million SEK | -2.14% |
| 2020 FY | 2.38 Million SEK | 59.41% |
| 2020 Q1 | 1.95 Million SEK | 30.68% |
| 2020 Q2 | 7.57 Million SEK | 288.47% |
| 2020 Q3 | 11.08 Million SEK | 46.25% |
| 2020 Q4 | 2.38 Million SEK | -78.53% |
| 2019 Q3 | 895 Thousand SEK | 40.94% |
| 2019 FY | 1.49 Million SEK | 61.58% |
| 2019 Q4 | 1.49 Million SEK | 66.82% |
| 2019 Q2 | 635 Thousand SEK | -46.5% |
| 2019 Q1 | 1.18 Million SEK | 28.46% |
| 2018 FY | 924 Thousand SEK | 1132.0% |
| 2018 Q2 | 411 Thousand SEK | 504.41% |
| 2018 Q4 | 924 Thousand SEK | 38.53% |
| 2018 Q1 | 68 Thousand SEK | -9.33% |
| 2018 Q3 | 667 Thousand SEK | 62.29% |
| 2017 Q2 | 1.05 Million SEK | 51.22% |
| 2017 Q1 | 695 Thousand SEK | 0.0% |
| 2017 Q4 | 75 Thousand SEK | 70.45% |
| 2017 FY | 75 Thousand SEK | -98.72% |
| 2017 Q3 | 44 Thousand SEK | -95.81% |
| 2016 Q1 | 1.16 Million SEK | 0.0% |
| 2016 Q4 | - SEK | -100.0% |
| 2016 Q3 | 1.16 Million SEK | 2.11% |
| 2016 Q2 | 1.13 Million SEK | -2.1% |
| 2016 FY | 5.87 Million SEK | 410.74% |
| 2015 FY | 1.14 Million SEK | 112.46% |
| 2014 FY | 541.14 Thousand SEK | 716.47% |
| 2013 FY | 66.27 Thousand SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Active Biotech AB (publ) | 3 Million SEK | 42.967% |
| Biovica International AB (publ) | 7.82 Million SEK | 78.143% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| CombiGene AB (publ) | - SEK | -Infinity% |
| Cyxone AB (publ) | 858 Thousand SEK | -99.417% |
| Diagonal Bio AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Mendus AB (publ) | 24.48 Million SEK | 93.013% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| I-Tech AB | - SEK | -Infinity% |
| Intervacc AB (publ) | 181 Thousand SEK | -845.304% |
| Lipigon Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 60.3 Million SEK | 97.163% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| OncoZenge AB (publ) | - SEK | -Infinity% |
| Sprint Bioscience AB (publ) | - SEK | -Infinity% |
| Xbrane Biopharma AB (publ) | 231.47 Million SEK | 99.261% |
| Lipum AB (publ) | 1.76 Million SEK | 2.839% |
| Alligator Bioscience AB (publ) | 16.09 Million SEK | 89.371% |
| Ziccum AB (publ) | 857 Thousand SEK | -99.65% |
| BioArctic AB (publ) | 4.97 Million SEK | 65.636% |
| Genovis AB (publ.) | 79.32 Million SEK | 97.843% |
| Camurus AB (publ) | 24.5 Million SEK | 93.018% |
| IRLAB Therapeutics AB (publ) | 27.56 Million SEK | 93.793% |
| Bio-Works Technologies AB (publ) | - SEK | -Infinity% |
| Aptahem AB (publ) | 5 Million SEK | 65.78% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Xspray Pharma AB (publ) | 36.8 Million SEK | 95.352% |
| Kancera AB (publ) | - SEK | -Infinity% |
| Saniona AB (publ) | 71.4 Million SEK | 97.604% |
| Spago Nanomedical AB (publ) | - SEK | -Infinity% |
| AcouSort AB (publ) | - SEK | -Infinity% |
| Xintela AB (publ) | - SEK | -Infinity% |
| Abliva AB (publ) | 424 Thousand SEK | -303.538% |
| Karolinska Development AB (publ) | 3.07 Million SEK | 44.267% |
| Amniotics AB (publ) | 2.58 Million SEK | 33.682% |
| 2cureX AB (publ) | - SEK | -Infinity% |
| Asarina Pharma AB (publ) | 1 Million SEK | -71.1% |
| Calliditas Therapeutics AB (publ) | 979.13 Million SEK | 99.825% |
| Hansa Biopharma AB (publ) | 866.76 Million SEK | 99.803% |
| Biosergen AB | - SEK | -Infinity% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.61 Million SEK | 91.699% |
| Corline Biomedical AB | - SEK | -Infinity% |
| NextCell Pharma AB | - SEK | -Infinity% |
| Nanologica AB (publ) | 666 Thousand SEK | -156.907% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Egetis Therapeutics AB (publ) | 108.6 Million SEK | 98.424% |
| BioInvent International AB (publ) | 23.24 Million SEK | 92.639% |
| SynAct Pharma AB | 637 Thousand SEK | -168.603% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | 850 Thousand SEK | -101.294% |
| Alzinova AB (publ) | 800 Thousand SEK | -113.875% |
| Ascelia Pharma AB (publ) | 1.06 Million SEK | -61.263% |
| Oncopeptides AB (publ) | 106.48 Million SEK | 98.393% |
| Pila Pharma AB (publ) | 773.08 Thousand SEK | -121.323% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | - SEK | -Infinity% |
| Simris Alg AB (publ) | 90.74 Million SEK | 98.114% |
| Diamyd Medical AB (publ) | 30.67 Million SEK | 94.422% |